ID PRAG1_HUMAN Reviewed; 1406 AA. AC Q86YV5; Q8N3N5; DT 28-NOV-2006, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-2014, sequence version 4. DT 27-MAR-2024, entry version 165. DE RecName: Full=Inactive tyrosine-protein kinase PRAG1 {ECO:0000305}; DE AltName: Full=PEAK1-related kinase-activating pseudokinase 1; DE AltName: Full=Pragmin {ECO:0000303|PubMed:27116701}; DE AltName: Full=Sugen kinase 223 {ECO:0000303|PubMed:29079850}; DE Short=SgK223; GN Name=PRAG1 {ECO:0000312|HGNC:HGNC:25438}; Synonyms=SGK223; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RX PubMed=16421571; DOI=10.1038/nature04406; RA Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M., RA Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L., RA Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S., RA Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A., RA Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III, RA Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., RA Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P., RA Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H., RA Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B., RA O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K., RA Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L., RA Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G., RA Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W., RA Platzer M., Shimizu N., Lander E.S.; RT "DNA sequence and analysis of human chromosome 8."; RL Nature 439:331-335(2006). RN [2] RP NUCLEOTIDE SEQUENCE [MRNA] OF 24-1406, AND VARIANTS GLN-404; LEU-569; RP CYS-578 AND THR-1113. RC TISSUE=Spleen; RA Jikuya H., Takano J., Nomura N., Kikuno R., Nagase T., Ohara O.; RT "The nucleotide sequence of a long cDNA clone isolated from human spleen."; RL Submitted (FEB-2003) to the EMBL/GenBank/DDBJ databases. RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 820-1406, AND VARIANT THR-1113. RC TISSUE=Amygdala; RX PubMed=17974005; DOI=10.1186/1471-2164-8-399; RA Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., RA Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., RA Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., RA Wiemann S., Schupp I.; RT "The full-ORF clone resource of the German cDNA consortium."; RL BMC Genomics 8:399-399(2007). RN [4] RP IDENTIFICATION. RX PubMed=12471243; DOI=10.1126/science.1075762; RA Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S.; RT "The protein kinase complement of the human genome."; RL Science 298:1912-1934(2002). RN [5] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-696 AND SER-745, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [6] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-745, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Leukemic T-cell; RX PubMed=19690332; DOI=10.1126/scisignal.2000007; RA Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K., RA Rodionov V., Han D.K.; RT "Quantitative phosphoproteomic analysis of T cell receptor signaling RT reveals system-wide modulation of protein-protein interactions."; RL Sci. Signal. 2:RA46-RA46(2009). RN [7] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-826, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21406692; DOI=10.1126/scisignal.2001570; RA Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T., RA Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.; RT "System-wide temporal characterization of the proteome and phosphoproteome RT of human embryonic stem cell differentiation."; RL Sci. Signal. 4:RS3-RS3(2011). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-148; SER-696 AND SER-826, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-148 AND SER-782, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [10] RP VARIANTS [LARGE SCALE ANALYSIS] ILE-122; GLY-137; ILE-139; GLN-404; RP LEU-569; CYS-578; ALA-595; THR-662; LEU-814; ARG-851; LEU-1003; MET-1041; RP THR-1113 AND HIS-1315. RX PubMed=17344846; DOI=10.1038/nature05610; RA Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., RA Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S., RA Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G., RA Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K., RA Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D., RA Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R., RA Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., RA Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F., RA Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F., RA Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G., RA Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R., RA Futreal P.A., Stratton M.R.; RT "Patterns of somatic mutation in human cancer genomes."; RL Nature 446:153-158(2007). RN [11] RP SUBCELLULAR LOCATION. RX PubMed=27116701; DOI=10.1111/cas.12962; RA Senda Y., Murata-Kamiya N., Hatakeyama M.; RT "C-terminal Src kinase-mediated EPIYA phosphorylation of Pragmin creates a RT feed-forward C-terminal Src kinase activation loop that promotes cell RT motility."; RL Cancer Sci. 107:972-980(2016). RN [12] {ECO:0007744|PDB:5VE6} RP X-RAY CRYSTALLOGRAPHY (2.95 ANGSTROMS) OF 932-1406, MUTAGENESIS OF LEU-955; RP LEU-966; ILE-1243; PHE-1271; ARG-1278; TYR-1282; PHE-1366 AND TRP-1382, RP SUBUNIT, INTERACTION WITH PEAK1, AND DOMAIN. RX PubMed=29079850; DOI=10.1038/s41467-017-01279-9; RA Patel O., Griffin M.D.W., Panjikar S., Dai W., Ma X., Chan H., Zheng C., RA Kropp A., Murphy J.M., Daly R.J., Lucet I.S.; RT "Structure of SgK223 pseudokinase reveals novel mechanisms of homotypic and RT heterotypic association."; RL Nat. Commun. 8:1157-1157(2017). CC -!- FUNCTION: Catalytically inactive protein kinase that acts as a scaffold CC protein. Functions as an effector of the small GTPase RND2, which CC stimulates RhoA activity and inhibits NGF-induced neurite outgrowth (By CC similarity). Promotes Src family kinase (SFK) signaling by regulating CC the subcellular localization of CSK, a negative regulator of these CC kinases, leading to the regulation of cell morphology and motility by a CC CSK-dependent mechanism (By similarity). Acts as a critical coactivator CC of Notch signaling (By similarity). {ECO:0000250|UniProtKB:D3ZMK9, CC ECO:0000250|UniProtKB:Q571I4}. CC -!- SUBUNIT: Homodimer (PubMed:29079850). Dimerization leads to the CC catalytic activation of CSK (By similarity). Interacts (via C-terminus) CC with RND2 (By similarity). Interacts with CSK (via SH2 domain) in a CC Tyr-413 phosphorylation-dependent manner; this interaction potentiates CC kinase activity of CSK (By similarity). Interacts with PEAK1 CC (PubMed:29079850). Interacts with NOTCH1 intracellular domain (N1ICD) CC (By similarity). Forms a complex with N1ICD and MAML1, in a MAML1- CC dependent manner (By similarity). {ECO:0000250|UniProtKB:D3ZMK9, CC ECO:0000250|UniProtKB:Q571I4, ECO:0000269|PubMed:29079850}. CC -!- INTERACTION: CC Q86YV5; P31947: SFN; NbExp=2; IntAct=EBI-719420, EBI-476295; CC Q86YV5; P62258: YWHAE; NbExp=2; IntAct=EBI-719420, EBI-356498; CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:D3ZMK9}. Cell CC junction, focal adhesion {ECO:0000269|PubMed:27116701}. Nucleus CC {ECO:0000250|UniProtKB:Q571I4}. Note=Colocalized with NOTCH1 in the CC nucleus. {ECO:0000250|UniProtKB:Q571I4}. CC -!- DOMAIN: The dimerization region encompasses helices both from the CC N- and C-terminal of the protein kinase domain. CC {ECO:0000269|PubMed:29079850}. CC -!- PTM: Phosphorylated by CSK on Tyr-253, Tyr-365, and Tyr-413; Tyr-413 is CC a primary site of phosphorylation. {ECO:0000250|UniProtKB:D3ZMK9}. CC -!- SIMILARITY: Belongs to the protein kinase superfamily. {ECO:0000305}. CC -!- CAUTION: Despite of the presence of a putative ATP-binding motif, this CC protein does not bind ATP, suggesting that it has no protein kinase CC activity. {ECO:0000250|UniProtKB:D3ZMK9}. CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AC068353; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AC103957; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AK122582; BAC56923.1; -; mRNA. DR EMBL; AL833872; CAD38729.1; -; mRNA. DR CCDS; CCDS43706.1; -. DR RefSeq; NP_001074295.2; NM_001080826.2. DR RefSeq; XP_005272426.2; XM_005272369.4. DR RefSeq; XP_005272427.2; XM_005272370.4. DR PDB; 5VE6; X-ray; 2.95 A; A=932-1406. DR PDB; 8DGN; X-ray; 3.16 A; B=812-831. DR PDBsum; 5VE6; -. DR PDBsum; 8DGN; -. DR AlphaFoldDB; Q86YV5; -. DR SMR; Q86YV5; -. DR BioGRID; 127591; 29. DR IntAct; Q86YV5; 13. DR MINT; Q86YV5; -. DR STRING; 9606.ENSP00000481109; -. DR iPTMnet; Q86YV5; -. DR PhosphoSitePlus; Q86YV5; -. DR BioMuta; PRAG1; -. DR DMDM; 327478560; -. DR CPTAC; non-CPTAC-5650; -. DR CPTAC; non-CPTAC-5651; -. DR EPD; Q86YV5; -. DR jPOST; Q86YV5; -. DR MassIVE; Q86YV5; -. DR PaxDb; 9606-ENSP00000481109; -. DR PeptideAtlas; Q86YV5; -. DR ProteomicsDB; 70475; -. DR Pumba; Q86YV5; -. DR Antibodypedia; 73468; 150 antibodies from 28 providers. DR DNASU; 157285; -. DR Ensembl; ENST00000615670.5; ENSP00000481109.1; ENSG00000275342.6. DR GeneID; 157285; -. DR KEGG; hsa:157285; -. DR MANE-Select; ENST00000615670.5; ENSP00000481109.1; NM_001080826.3; NP_001074295.2. DR UCSC; uc064kbu.1; human. DR AGR; HGNC:25438; -. DR DisGeNET; 157285; -. DR GeneCards; PRAG1; -. DR HGNC; HGNC:25438; PRAG1. DR HPA; ENSG00000275342; Tissue enhanced (brain, thyroid gland). DR MIM; 617344; gene. DR neXtProt; NX_Q86YV5; -. DR OpenTargets; ENSG00000275342; -. DR VEuPathDB; HostDB:ENSG00000275342; -. DR eggNOG; ENOG502QVUZ; Eukaryota. DR GeneTree; ENSGT00940000157066; -. DR HOGENOM; CLU_005467_0_0_1; -. DR InParanoid; Q86YV5; -. DR OMA; DLKMSAC; -. DR OrthoDB; 2914135at2759; -. DR PathwayCommons; Q86YV5; -. DR Reactome; R-HSA-9696270; RND2 GTPase cycle. DR SignaLink; Q86YV5; -. DR BioGRID-ORCS; 157285; 22 hits in 1121 CRISPR screens. DR ChiTaRS; SGK223; human. DR GenomeRNAi; 157285; -. DR Pharos; Q86YV5; Tbio. DR PRO; PR:Q86YV5; -. DR Proteomes; UP000005640; Chromosome 8. DR RNAct; Q86YV5; Protein. DR Bgee; ENSG00000275342; Expressed in cerebellar vermis and 184 other cell types or tissues. DR GO; GO:0005737; C:cytoplasm; ISS:UniProtKB. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0005925; C:focal adhesion; IDA:UniProtKB. DR GO; GO:0005634; C:nucleus; ISS:UniProtKB. DR GO; GO:0042802; F:identical protein binding; IDA:UniProtKB. DR GO; GO:0004672; F:protein kinase activity; IBA:GO_Central. DR GO; GO:0016477; P:cell migration; IMP:UniProtKB. DR GO; GO:0010977; P:negative regulation of neuron projection development; ISS:UniProtKB. DR GO; GO:0035025; P:positive regulation of Rho protein signal transduction; ISS:UniProtKB. DR GO; GO:2000145; P:regulation of cell motility; ISS:UniProtKB. DR GO; GO:0008360; P:regulation of cell shape; ISS:UniProtKB. DR GO; GO:0008593; P:regulation of Notch signaling pathway; ISS:UniProtKB. DR DisProt; DP02420; -. DR Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1. DR InterPro; IPR011009; Kinase-like_dom_sf. DR InterPro; IPR000719; Prot_kinase_dom. DR InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom. DR InterPro; IPR008266; Tyr_kinase_AS. DR PANTHER; PTHR22972:SF3; INACTIVE TYROSINE-PROTEIN KINASE PRAG1; 1. DR PANTHER; PTHR22972; SERINE/THREONINE PROTEIN KINASE; 1. DR Pfam; PF07714; PK_Tyr_Ser-Thr; 1. DR SMART; SM00220; S_TKc; 1. DR SUPFAM; SSF56112; Protein kinase-like (PK-like); 1. DR PROSITE; PS50011; PROTEIN_KINASE_DOM; 1. DR PROSITE; PS00109; PROTEIN_KINASE_TYR; 1. DR Genevisible; Q86YV5; HS. PE 1: Evidence at protein level; KW 3D-structure; Cell junction; Cytoplasm; Nucleus; Phosphoprotein; KW Reference proteome. FT CHAIN 1..1406 FT /note="Inactive tyrosine-protein kinase PRAG1" FT /id="PRO_0000263008" FT DOMAIN 978..1329 FT /note="Protein kinase" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00159" FT REGION 184..205 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 217..248 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 372..470 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 484..854 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 933..976 FT /note="Required for homodimerization" FT /evidence="ECO:0000250|UniProtKB:D3ZMK9" FT REGION 1163..1206 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1331..1406 FT /note="Required for homodimerization" FT /evidence="ECO:0000250|UniProtKB:D3ZMK9" FT COMPBIAS 502..529 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 530..544 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 603..630 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 654..692 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 730..784 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 828..851 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 1163..1181 FT /note="Pro residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 148 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163, FT ECO:0007744|PubMed:24275569" FT MOD_RES 253 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:D3ZMK9" FT MOD_RES 365 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:D3ZMK9" FT MOD_RES 413 FT /note="Phosphotyrosine" FT /evidence="ECO:0000250|UniProtKB:D3ZMK9" FT MOD_RES 696 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 745 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:19690332" FT MOD_RES 782 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 826 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:21406692, FT ECO:0007744|PubMed:23186163" FT VARIANT 122 FT /note="L -> I (in dbSNP:rs55764617)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041803" FT VARIANT 137 FT /note="R -> G (in dbSNP:rs56290960)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041804" FT VARIANT 139 FT /note="V -> I (in dbSNP:rs34346032)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041805" FT VARIANT 404 FT /note="R -> Q (in dbSNP:rs3896980)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.2" FT /id="VAR_041806" FT VARIANT 569 FT /note="P -> L (in dbSNP:rs4840955)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.2" FT /id="VAR_041807" FT VARIANT 578 FT /note="S -> C (in dbSNP:rs4840953)" FT /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.2" FT /id="VAR_041808" FT VARIANT 595 FT /note="P -> A (in dbSNP:rs55994745)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041809" FT VARIANT 662 FT /note="P -> T (in dbSNP:rs56351643)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041810" FT VARIANT 814 FT /note="P -> L (in dbSNP:rs56207906)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041811" FT VARIANT 851 FT /note="H -> R (in dbSNP:rs56215812)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041812" FT VARIANT 1003 FT /note="S -> L (in dbSNP:rs56289289)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041813" FT VARIANT 1041 FT /note="V -> M (in dbSNP:rs28533138)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041814" FT VARIANT 1113 FT /note="A -> T (in dbSNP:rs12549973)" FT /evidence="ECO:0000269|PubMed:17344846, FT ECO:0000269|PubMed:17974005, ECO:0000269|Ref.2" FT /id="VAR_041815" FT VARIANT 1315 FT /note="R -> H (in dbSNP:rs1314830862)" FT /evidence="ECO:0000269|PubMed:17344846" FT /id="VAR_041816" FT MUTAGEN 955 FT /note="L->A: Decreases homodimerization. Abolished FT interaction with PEAK1. No effect on cell migration." FT /evidence="ECO:0000269|PubMed:29079850" FT MUTAGEN 966 FT /note="L->A: Decreases homodimerization. Abolished FT interaction with PEAK1. Decreases cell migration." FT /evidence="ECO:0000269|PubMed:29079850" FT MUTAGEN 1243 FT /note="I->A: No effect on homodimerization. Decreases FT oligomerization. Decreases interaction with PEAK1." FT /evidence="ECO:0000269|PubMed:29079850" FT MUTAGEN 1271 FT /note="F->A: Decreases homodimerization. Decreases FT interaction with PEAK1." FT /evidence="ECO:0000269|PubMed:29079850" FT MUTAGEN 1278 FT /note="R->A: Decreases homodimerization." FT /evidence="ECO:0000269|PubMed:29079850" FT MUTAGEN 1282 FT /note="Y->A: No effect on homodimerization. Decreases FT oligomerization. Decreases interaction with PEAK1. No FT effect on cell migration." FT /evidence="ECO:0000269|PubMed:29079850" FT MUTAGEN 1366 FT /note="F->A: Decreases homodimerization. Abolished FT interaction with PEAK1. Decreases cell migration." FT /evidence="ECO:0000269|PubMed:29079850" FT MUTAGEN 1382 FT /note="W->A: Decreases homodimerization. Abolished FT interaction with PEAK1. Decreases cell migration." FT /evidence="ECO:0000269|PubMed:29079850" FT CONFLICT 1226 FT /note="G -> S (in Ref. 2; BAC56923 and 3; CAD38729)" FT /evidence="ECO:0000305" FT HELIX 948..974 FT /evidence="ECO:0007829|PDB:5VE6" FT HELIX 988..991 FT /evidence="ECO:0007829|PDB:5VE6" FT STRAND 992..995 FT /evidence="ECO:0007829|PDB:5VE6" FT STRAND 1000..1002 FT /evidence="ECO:0007829|PDB:5VE6" FT STRAND 1004..1016 FT /evidence="ECO:0007829|PDB:5VE6" FT STRAND 1020..1026 FT /evidence="ECO:0007829|PDB:5VE6" FT STRAND 1050..1059 FT /evidence="ECO:0007829|PDB:5VE6" FT HELIX 1060..1063 FT /evidence="ECO:0007829|PDB:5VE6" FT STRAND 1084..1094 FT /evidence="ECO:0007829|PDB:5VE6" FT STRAND 1096..1099 FT /evidence="ECO:0007829|PDB:5VE6" FT HELIX 1100..1105 FT /evidence="ECO:0007829|PDB:5VE6" FT HELIX 1108..1113 FT /evidence="ECO:0007829|PDB:5VE6" FT HELIX 1115..1138 FT /evidence="ECO:0007829|PDB:5VE6" FT HELIX 1148..1150 FT /evidence="ECO:0007829|PDB:5VE6" FT STRAND 1151..1154 FT /evidence="ECO:0007829|PDB:5VE6" FT STRAND 1211..1214 FT /evidence="ECO:0007829|PDB:5VE6" FT HELIX 1246..1250 FT /evidence="ECO:0007829|PDB:5VE6" FT HELIX 1252..1264 FT /evidence="ECO:0007829|PDB:5VE6" FT HELIX 1270..1272 FT /evidence="ECO:0007829|PDB:5VE6" FT HELIX 1275..1279 FT /evidence="ECO:0007829|PDB:5VE6" FT HELIX 1284..1286 FT /evidence="ECO:0007829|PDB:5VE6" FT HELIX 1296..1307 FT /evidence="ECO:0007829|PDB:5VE6" FT TURN 1312..1314 FT /evidence="ECO:0007829|PDB:5VE6" FT HELIX 1318..1329 FT /evidence="ECO:0007829|PDB:5VE6" FT HELIX 1348..1369 FT /evidence="ECO:0007829|PDB:5VE6" FT HELIX 1379..1389 FT /evidence="ECO:0007829|PDB:5VE6" FT HELIX 1393..1402 FT /evidence="ECO:0007829|PDB:5VE6" SQ SEQUENCE 1406 AA; 149624 MW; 941BCF315B826148 CRC64; MHQTLCLNPE SLKMSACSDF VEHIWKPGSC KNCFCLRSDH QLVAGPPQPR AGSLPPPPRL PPRPENCRLE DEGVNSSPYS KPTIAVKPTM MSSEASDVWT EANLSAEVSQ VIWRRAPGKL PLPKQEDAPV VYLGSFRGVQ KPAGPSTSPD GNSRCPPAYT MVGLHNLEPR GERNIAFHPV SFPEEKAVHK EKPSFPYQDR PSTQESFRQK LAAFAGTTSG CHQGPGPLRE SLPSEDDSDQ RCSPSGDSEG GEYCSILDCC PGSPVAKAAS QTAGSRGRHG GRDCSPTCWE QGKCSGPAEQ EKRGPSFPKE CCSQGPTAHP SCLGPKKLSL TSEAAISSDG LSCGSGSGSG SGASSPFVPH LESDYCSLMK EPAPEKQQDP GCPGVTPSRC LGLTGEPQPP AHPREATQPE PIYAESTKRK KAAPVPSKSQ AKIEHAAAAQ GQGQVCTGNA WAQKAASGWG RDSPDPTPQV SATITVMAAH PEEDHRTIYL SSPDSAVGVQ WPRGPVSQNS EVGEEETSAG QGLSSRESHA HSASESKPKE RPAIPPKLSK SSPVGSPVSP SAGGPPVSPL ADLSDGSSGG SSIGPQPPSQ GPADPAPSCR TNGVAISDPS RCPQPAASSA SEQRRPRFQA GTWSRQCRIE EEEEVEQELL SHSWGRETKN GPTDHSNSTT WHRLHPTDGS SGQNSKVGTG MSKSASFAFE FPKDRSGIET FSPPPPPPKS RHLLKMNKSS SDLEKVSQGS AESLSPSFRG VHVSFTTGST DSLASDSRTC SDGGPSSELA HSPTNSGKKL FAPVPFPSGS TEDVSPSGPQ QPPPLPQKKI VSRAASSPDG FFWTQGSPKP GTASPKLNLS HSETNVHDES HFSYSLSPGN RHHPVFSSSD PLEKAFKGSG HWLPAAGLAG NRGGCGSPGL QCKGAPSASS SQLSVSSQAS TGSTQLQLHG LLSNISSKEG TYAKLGGLYT QSLARLVAKC EDLFMGGQKK ELHFNENNWS LFKLTCNKPC CDSGDAIYYC ATCSEDPGST YAVKICKAPE PKTVSYCSPS VPVHFNIQQD CGHFVASVPS SMLSSPDAPK DPVPALPTHP PAQEQDCVVV ITREVPHQTA SDFVRDSAAS HQAEPEAYER RVCFLLLQLC NGLEHLKEHG IIHRDLCLEN LLLVHCTLQA GPGPAPAPAP APAPAAAAPP CSSAAPPAGG TLSPAAGPAS PEGPREKQLP RLIISNFLKA KQKPGGTPNL QQKKSQARLA PEIVSASQYR KFDEFQTGIL IYELLHQPNP FEVRAQLRER DYRQEDLPPL PALSLYSPGL QQLAHLLLEA DPIKRIRIGE AKRVLQCLLW GPRRELVQQP GTSEEALCGT LHNWIDMKRA LMMMKFAEKA VDRRRGVELE DWLCCQYLAS AEPGALLQSL KLLQLL //